Ocugen Inc (OCGN)
$0.22
0.01 (4.30%)
OCGN Stock Quote Delayed 30 Minutes
Previous Close
$0.21
Market Cap
-
PE Ratio
-
EPS
-
Volume (Avg. Vol.)
5.98M
Day's Range
0.21 - 0.22
52-Week Range
0.17 - 8.62
Dividend & Yield
N/A (N/A)
OCGN Stock Predictions, Articles, and Ocugen Inc News
Ocugen Stock Is a Gamble, Not an Investment Opportunity
Some investors make a profession by scouring penny stocks like Ocugen. For me, I like sound business over a gamble in OCGN stock.
This Is No Time to Be Speculating on Ocugen
Ocugen's ambitions are not gaining traction in an environment where most biotech investors are focusing on Covid-19. Thus, the case for OCGN stock is unusually risky.
Don’t Make a Blind Investment In Ocugen Stock
After Ocugen recently disappointed in a late-stage trial for one of its therapies, OCGN stock jumped higher. Is this a legitimate rally or merely a dead cat bounce?
Ocugen Stock Offers Investors a Simple Value Proposition
Although Ocugen stock has a narrow window for tremendous upside, the broader threats of today make OCGN an extreme gamble.
Always Risky OCGN Stock Just Got More Treacherous
Even in the best of circumstances, OCGN stock was never for the faint of heart. With the coronavirus raging everywhere, I’m not sure for whom Ocugen is appropriate.
All Bets Are off for Speculative Long-Shot Ocugen Stock
With this in mind, the best bet is to avoid Ocugen stock. Shares could skyrocket if OCU300 shows positive top-line results. Conversely, shares could fall to new lows if results do not match expectations. It may be temping to place a buy order and hope for the best. But, long-term, investing success requires discretion, not speculation. Seek more solid opportunities elsewhere, and put Ocugen on hold for now.
High-Risk Ocugen Needs Good Trial Results to Survive
Ocugen stock has fallen far, and needs positive trial results for its OCU300 treatment to turn things around. For now, it's a high-risk play.
Ocugen Is a Bold Biotech Bet, But the Payoff Could Be Rich
A pipeline of treatments for underserved eye conditions like oGVHD makes OCGN stock worth considering as part of your biotech holdings.
Ocugen Stock Might be up 34% in 2020 but There are Other Eye Care Plays
Except for a couple of specific investors, Ocugen stock is not one for average people. Instead, look at Bausch Health Companies, which has a very rocky backstory but has managed to turn the corner.
Ocugen Stock Is Not for the Faint of Heart
Ocugen stock has an intriguing bull case based on its pipeline. But the nano-cap biotech is as risky as any stock in the space.
Avoid Ocugen Stock as Science and the Markets Clash
OCGN stock makes an attractive speculative case because of the underlying company’s potential to address rare eye diseases. Still, this is an opportunity that only risk-takers with “dumb money” should engage.
For Penny Investors, Ocugen Stock Makes a Good Speculative Play
With two orphan drug designations and a promising partnership, Ocugen stock makes a good play for speculative investors.
With No Revenue or Approved Treatments, Ocugen Stock Is a Clear Sell
How Ocugen stock came to be makes no sense. Neither does the idea that investors will continue to pour money into this cesspool.
Ocugen Stock Is Nothing More than a Risky Trade on Even-riskier Biotech
Ocugen gave rise to OCGN stock through a reverse merger with Histogenics. But despite this confusing deal, it really didn't do much for either company in the end.
Ocugen News: OCGN Stock Soars 40% on Stock Buyback Plan
Ocugen (OCGN) news for Wednesday about a massive stock buyback plan for $2 million worth of shares has OCGN stock on the move.
Navellier Ratings
Powered by Portfolio GraderTotal Grade
F
